Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties
Authors
Keywords
Hepatocellular carcinoma, Gene expression, Spleen, Flow cytometry, Stem cell lines, Lung and intrathoracic tumors, Mouse models, Secondary lung tumors
Journal
PLoS One
Volume 12, Issue 2, Pages e0171215
Publisher
Public Library of Science (PLoS)
Online
2017-02-03
DOI
10.1371/journal.pone.0171215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- p28GANK Prevents Degradation of Oct4 and Promotes Expansion of Tumor-Initiating Cells in Hepatocarcinogenesis
- (2012) You–Wen Qian et al. GASTROENTEROLOGY
- CD133+EpCAM+ Phenotype Possesses More Characteristics of Tumor Initiating Cells in Hepatocellular Carcinoma Huh7 Cells
- (2012) Yi Chen et al. International Journal of Biological Sciences
- EpCAM regulates cell cycle progression via control of cyclin D1 expression
- (2012) A Chaves-Pérez et al. ONCOGENE
- Upregulator of Cell Proliferation Predicts Poor Prognosis in Hepatocellular Carcinoma and Contributes to Hepatocarcinogenesis by Downregulating FOXO3a
- (2012) Chan Xie et al. PLoS One
- E-cadherin is under constitutive actomyosin-generated tension that is increased at cell-cell contacts upon externally applied stretch
- (2012) N. Borghi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EpCAM and its potential role in tumor-initiating cells
- (2012) Sannia Imrich et al. Cell Adhesion & Migration
- Liver Fibrosis Protects Mice From Acute Hepatocellular Injury
- (2011) Éric Bourbonnais et al. GASTROENTEROLOGY
- Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
- (2011) Jianjun Zhou et al. Molecular Cancer
- Models of carcinogenesis: an overview
- (2010) P. Vineis et al. CARCINOGENESIS
- Quantifying growth and transformation frequency of oncogene-expressing mouse hepatocytes in vivo
- (2010) Marxa L. Figueiredo et al. HEPATOLOGY
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Non-viral causes of hepatocellular carcinoma
- (2010) Wojciech Blonski WORLD JOURNAL OF GASTROENTEROLOGY
- Initial activation of EpCAM cleavage viacell-to-cell contact
- (2009) Sabine Denzel et al. BMC CANCER
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation
- (2009) Weifei Wang et al. CANCER SCIENCE
- Role of Wnt/β-catenin signaling in liver metabolism and cancer
- (2009) Satdarshan Pal Singh Monga INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Experimental mouse models for hepatocellular carcinoma research
- (2009) Femke Heindryckx et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer
- (2009) Du Wenqi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Looking ahead in cancer stem cell research
- (2009) John E Dick NATURE BIOTECHNOLOGY
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
- (2008) Taro Yamashita et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More